OncoMatch/Clinical Trials/NCT07106684
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
Is NCT07106684 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including BCMA CAR-T and GPRC5D/CD3 BiTEs for multiple myeloma, plasma cell leukemia.
Treatment: BCMA CAR-T · GPRC5D/CD3 BiTEs — This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of autologous stem cell transplantation combined with BCMA CAR-T therapy followed by GPRC5D/CD3 bispecific antibody maintenance in transplant-eligible patients with primary plasma cell leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) overexpression (positive)
Tumor cells were BCMA ... positive
Required: GPRC5D overexpression (positive)
Tumor cells were ... GPRC5D positive
Prior therapy
Cannot have received: BCMA-targeted therapy
Prior BCMA-targeted therapy
Cannot have received: CAR-T cell therapy
Prior ... CAR-T therapy
Lab requirements
Kidney function
creatinine clearance ≥ 30ml/min (cockroft-gault formula)
Liver function
serum total bilirubin <2 x uln, serum ast and alt <3 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify